Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02729467 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT02729467 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 33 participants.
The verdict
NCT02729467, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of itraconazole, a strong cytochrome P (CYP)3A4 and p-glycoprotein (PgP) inhibitor, and rifampicin, a CYP3A4, uridine 5'-diphospho-glucuronosyltransferase (UGT), and PgP inducer, and an inhibitor of organic anion-transporting polypeptide (OATP), on the single-dose pharmacokinetics (PK) of JNJ-53718678 in healthy adult participants.
Interventions
- DRUG Itraconazole
- DRUG Rifampicin
- DRUG JNJ-53718678
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-03 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02729467
The ClinicalTrials.gov registry entry for NCT02729467 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Itraconazole is the first listed.
NCT02729467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02729467 about?
NCT02729467 is a clinical study titled "A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults". The purpose of this study is to assess the effects of itraconazole, a strong cytochrome P (CYP)3A4 and p-glycoprotein (PgP) inhibitor, and rifampicin, a CYP3A4, uridine 5'-diphospho-glucuronosyltransferase (UGT), and PgP inducer, and an inhibitor of organic anion-transporting polypeptide (OATP), on ...
What is the current status of trial NCT02729467?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2016-03. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02729467?
The interventions under investigation include: Itraconazole (DRUG), Rifampicin (DRUG), JNJ-53718678 (DRUG).
Who is sponsoring clinical trial NCT02729467?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.